In this episode, Joseph J. Eron, Jr., MD, explores whether weight gain should or should not be a factor in determining initial therapy.Listen as he gives his perspectives on:Weight gain following ART initiation by ARV class and ARV drugResults of the ADVANCE and GEMINI-1 and -2 studies, with exploration of weight, risk of CVD and diabetesBMI changes in PWHDHHS and IAS-USA guidelines for initial therapyPresenter:Joseph J. Eron, MDProfessor of Medicine and EpidemiologyUniversity of North Carolina  School of MedicineDirector, AIDS Clinical Trials UnitUniversity of North CarolinaChapel Hill, North CarolinaFollow along with the slides at:https://bit.ly/3DyLgA3See the entire program at:https://bit.ly/2TXTYWx